Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19331977 | 0.88 | MAPT (0.57) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL27841939 | 0.85 | MAPT (0.61) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL14874247 | 0.84 | MAPT (0.62) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL19332026 | 0.83 | PTGS2 (0.53) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL19332027 | 0.83 | PTGS2 (0.53) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL2550565 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL2462903 | 0.82 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL2559467 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL29951762 | 0.79 | ALDH1A1 (0.51) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL22324323 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11801315-B2 | Radioligands for myelin | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801315-B2 | Radioligands for myelin | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230201382-A1 | RADIOLIGANDS FOR MYELIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-29 | — | — | US | disclosed |
| US-20230201382-A1 | RADIOLIGANDS FOR MYELIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-29 | — | — | US | disclosed |
| EP-3426309-B1 | RADIOLIGANDS FOR MYELIN | UNIV CASE WESTERN RESERVE (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20210128756-A1 | RADIOLIGANDS FOR MYELIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10765763-B2 | Radioligands for myelin | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190134232-A1 | RADIOLIGANDS FOR MYELIN | CASE WESTERN RESERVE UNIVERSITY | 2019-05-09 | — | — | US | disclosed |
| EP-3426309-A1 | RADIOLIGANDS FOR MYELIN | Case Western Reserve University (US) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017156303-A1 | RADIOLIGANDS FOR MYELIN | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156303-A1 | RADIOLIGANDS FOR MYELIN | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134232-A1 | RADIOLIGANDS FOR MYELIN | MAG, PMP22, MYT1 | ALDH1A1 3084/4885MAPT 1625/4885HPGD 2564/4885 |
| US-20230201382-A1 | RADIOLIGANDS FOR MYELIN | MAG, PMP22, MYT1 | ALDH1A1 2144/4885MAPT 2373/4885HPGD 852/4885 |
| US-20210128756-A1 | RADIOLIGANDS FOR MYELIN | MAG, PMP22, MYT1 | ALDH1A1 3084/4885MAPT 1625/4885HPGD 2564/4885 |
| US-11801315-B2 | Radioligands for myelin | MAG, PMP22, MYT1 | ALDH1A1 3084/4885MAPT 1625/4885HPGD 2564/4885 |
| US-10765763-B2 | Radioligands for myelin | MAG, PMP22, MYT1 | ALDH1A1 3084/4885MAPT 1625/4885HPGD 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.